Greenwich Lifesciences Provides Update On Commercial Manufacturing
In 2024, additional refinements were made towards finalizing the manufacturing of GP2, the reconstitution of GLSI-100 in the pharmacy, and the injection of GLSI-100 in the clinic. As a result, the ...
Peripheral Arterial Disease Pipeline, Clinical Trials, Emerging Drugs Approvals And Companies Delveinsight
.Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for ...